Mylan/Biocon Running Out Of Time To Get Insulin Approved Before US Transition

 
• By Michael Cipriano
  
Time-flies
The clock continues to tick for Mylan and Biocon's insulin glargine NDA following another CRL.
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Biosimilars & Generics